{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:46:28Z","timestamp":1759333588441},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00105-006-1189-5","type":"journal-article","created":{"date-parts":[[2006,8,18]],"date-time":"2006-08-18T08:11:08Z","timestamp":1155888668000},"page":"744-755","source":"Crossref","is-referenced-by-count":1,"title":["Kutane Lymphome","Cutaneous lymphomas"],"prefix":"10.1007","volume":"57","author":[{"given":"R.","family":"Stadler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1189_CR1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","volume":"121","author":"Bunn","year":"1994","unstructured":"Bunn PA Jr, Hoffann SJ, Norris D et al. (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the S\u00e9zary syndrome). Ann Intern Med 121: 592\u2013602","journal-title":"Ann Intern Med"},{"key":"1189_CR2","first-page":"381","volume":"10","author":"Dummer","year":"2005","unstructured":"Dummer R (2005) Emerging drugs in cutaneous T-cell lymphomas. Expert Opin 10: 381\u2013392","journal-title":"Expert Opin"},{"key":"1189_CR3","first-page":"366","volume":"26","author":"Dummer","year":"2003","unstructured":"Dummer R, Kempf W, Hess Schmid M et al. (2003) Therapy of cutaneous lymphoma \u2013 current practice an future development. Onkologie 26: 366\u201372","journal-title":"Onkologie"},{"key":"1189_CR4","unstructured":"Dummer R, Stadler R, Sterry W (2005) Deutsche Leitlinie: Kutane Lymphome. In: Garbe C (Hrsg) Interdisziplin\u00e4re Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Georg Thieme, Stuttgart, S 83\u201395"},{"key":"1189_CR5","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J Clin Oncol 19: 2456\u20132471","journal-title":"J Clin Oncol"},{"key":"1189_CR6","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/sj.leu.2403984","volume":"19","author":"Faderl","year":"2005","unstructured":"Faderl S, Coutre S, Byrd JC et al. (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19: 2147\u20132152","journal-title":"Leukemia"},{"key":"1189_CR7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1586\/14737140.4.2.180","volume":"4","author":"Farol","year":"2004","unstructured":"Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4: 180\u2013188","journal-title":"Expert Rev Anticancer Ther"},{"key":"1189_CR8","doi-asserted-by":"crossref","unstructured":"Foss F (2003) Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymph 44 [Suppl 3]: S55\u201361","DOI":"10.1080\/10428190310001623757"},{"key":"1189_CR9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","volume":"106","author":"Foss","year":"2005","unstructured":"Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106: 454\u2013457","journal-title":"Blood"},{"key":"1189_CR10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/14712598.5.9.1225","volume":"5","author":"Jacobs","year":"2005","unstructured":"Jacobs SA, Foon KA (2005) Monoclonal antibody therapy of leukemias and lymphomas. Expert Opin Biol Ther 5: 1225\u20131243","journal-title":"Expert Opin Biol Ther"},{"key":"1189_CR11","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissue. IARC Press, Lyon"},{"key":"1189_CR12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"Johnstone","year":"2002","unstructured":"Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287\u2013299","journal-title":"Nat Rev Drug Discov"},{"key":"1189_CR13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","volume":"321","author":"Kaye","year":"1989","unstructured":"Kaye FJ, Bunn PA Jr, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321: 1784\u20131790","journal-title":"N Engl J Med"},{"key":"1189_CR14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","volume":"115","author":"Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK et al. (2005) Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest 115: 798\u2013812","journal-title":"J Clin Invest"},{"key":"1189_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2001.tb03716.x","volume":"94","author":"Knobler","year":"2001","unstructured":"Knobler R, Girardi M (2001) Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphomas. Ann NY Acad Sci 94: 123\u2013138","journal-title":"Ann NY Acad Sci"},{"key":"1189_CR16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"Olsen","year":"2001","unstructured":"Olsen E, Duvic M, Frankel A et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19: 376\u2013388","journal-title":"J Clin Oncol"},{"key":"1189_CR17","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","volume":"98","author":"Piekarz","year":"2001","unstructured":"Piekarz RL, Robey R, Sandor V et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901288), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865\u20132868","journal-title":"Blood"},{"key":"1189_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","volume":"141","author":"Querfeld","year":"2005","unstructured":"Querfeld C, Rosen ST, Kuzel TM et al. (2005) Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141: 305\u2013311","journal-title":"Arch Dermatol"},{"key":"1189_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","volume":"75","author":"Rupoli","year":"2005","unstructured":"Rupoli S, Goteri G, Pulini S et al. (2005) Long-term experience with low-dose interferon-\u03b1 and PUVA in the management of early mycosis fungoides. Eur J Haematol 75: 136\u2013145","journal-title":"Eur J Haematol"},{"key":"1189_CR20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/B:APPT.0000025805.55340.c3","volume":"9","author":"Schon","year":"2004","unstructured":"Schon MP, Schon M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9: 291\u2013298","journal-title":"Apoptosis"},{"key":"1189_CR21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0733-8635(05)70020-6","volume":"16","author":"Stadler","year":"1998","unstructured":"Stadler R (1998) Interferons in dermatology \u2013 present-day standard. Dermatol Clin 16: 377\u2013398","journal-title":"Dermatol Clin"},{"key":"1189_CR22","doi-asserted-by":"crossref","unstructured":"Stadler R, Kremer A (2006) Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol 33 [1 Suppl 3]: S7\u201310","DOI":"10.1053\/j.seminoncol.2005.12.016"},{"key":"1189_CR23","unstructured":"Stadler R, Otte HG (1997) Aktuelle Behandlungsstrategien kutaner Lymphome. Zeitschr Hautk H+G 72: 257\u2013262"},{"key":"1189_CR24","first-page":"3578","volume":"92","author":"Stadler","year":"1998","unstructured":"Stadler R, Otte HG, Luger T et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon \u03b1-2a plus acitretin versus intferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma, stages I and II. Blood 92: 3578\u20133581","journal-title":"Blood"},{"key":"1189_CR25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R et al. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome. Eur J Cancer 42: 1014\u20131030","journal-title":"Eur J Cancer"},{"key":"1189_CR26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/dji207","volume":"15","author":"Urosevic","year":"2005","unstructured":"Urosevic M, Dummer R, Contrad C et al. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod. J Nat Cancer Inst 15: 1143\u20131153","journal-title":"J Nat Cancer Inst"},{"key":"1189_CR27","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"van","year":"2003","unstructured":"van Dognen JJ, Langerak AW, Bruggemann M et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98\u20133936. Leukemia 17: 2257\u20132317","journal-title":"Leukemia"},{"key":"1189_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","volume":"46","author":"Vonderheid","year":"2002","unstructured":"Vonderheid EC, Berengo MG, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46: 95\u2013106","journal-title":"J Am Acad Dermatol"},{"key":"1189_CR29","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768\u20133785","journal-title":"Blood"},{"key":"1189_CR30","first-page":"354","volume":"90","author":"Willemze","year":"1997","unstructured":"Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of th European Organization for Research and Treatment of Cancer. Blood 90: 354\u2013371","journal-title":"Blood"},{"key":"1189_CR31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","volume":"98","author":"Wollina","year":"2003","unstructured":"Wollina U, Dummer R, Brockmeyer NH et al. (2003) Multicenter study of pegylated liposomal docorubicin in patients with cutaneous T-cell lymphoma. Cancer 98: 993\u20131001","journal-title":"Cancer"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1189-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1189-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:21:55Z","timestamp":1707182515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1189-5"}},"subtitle":["Klassifikationen und stadiengerechte Therapieoptionen","Classification and stage-adjusted therapy"],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1189-5","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}